122 related articles for article (PubMed ID: 34894066)
1. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome.
Iznardo H; Bredrup C; Bernal S; Gladkauskas T; Mascaró JM; Roé E; Baselga E
Am J Med Genet A; 2022 Apr; 188(4):1233-1238. PubMed ID: 34894066
[TBL] [Abstract][Full Text] [Related]
2. Penttinen syndrome-associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling.
Nédélec A; Guérit EM; Dachy G; Lenglez S; Wong LS; Arts FA; Demoulin JB
J Cell Mol Med; 2022 Jul; 26(14):3902-3912. PubMed ID: 35689379
[TBL] [Abstract][Full Text] [Related]
3. A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.
Bredrup C; Stokowy T; McGaughran J; Lee S; Sapkota D; Cristea I; Xu L; Tveit KS; Høvding G; Steen VM; Rødahl E; Bruland O; Houge G
Eur J Hum Genet; 2019 Apr; 27(4):574-581. PubMed ID: 30573803
[TBL] [Abstract][Full Text] [Related]
4. A Point Mutation in PDGFRB Causes Autosomal-Dominant Penttinen Syndrome.
Johnston JJ; Sanchez-Contreras MY; Keppler-Noreuil KM; Sapp J; Crenshaw M; Finch NA; Cormier-Daire V; Rademakers R; Sybert VP; Biesecker LG
Am J Hum Genet; 2015 Sep; 97(3):465-74. PubMed ID: 26279204
[TBL] [Abstract][Full Text] [Related]
5. First case report of Penttinen syndrome from India.
Aggarwal B; Correa ARE; Gupta N; Jana M; Kabra M
Am J Med Genet A; 2022 Feb; 188(2):683-687. PubMed ID: 34799960
[TBL] [Abstract][Full Text] [Related]
6. PDGFRB mutation causes autosomal-dominant Penttinen syndrome.
Aminkeng F
Clin Genet; 2015 Dec; 88(6):531. PubMed ID: 26507258
[TBL] [Abstract][Full Text] [Related]
7. Premature Aging Syndrome, Penttinen Type: Report of a Chinese Case with a PDGFRB Mutation.
Zhang Z; Zheng S; Zheng S; Wang Y; Xu XG; Gao XH; Chen HD
Acta Derm Venereol; 2018 Oct; 98(9):912-913. PubMed ID: 29944170
[No Abstract] [Full Text] [Related]
8. Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions.
Bredrup C; Cristea I; Safieh LA; Di Maria E; Gjertsen BT; Tveit KS; Thu F; Bull N; Edward DP; Hennekam RCM; Høvding G; Haugen OH; Houge G; Rødahl E; Bruland O
Hum Mol Genet; 2021 Mar; 30(1):72-77. PubMed ID: 33450762
[TBL] [Abstract][Full Text] [Related]
9. A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.
Pond D; Arts FA; Mendelsohn NJ; Demoulin JB; Scharer G; Messinger Y
Genet Med; 2018 Jan; 20(1):142-150. PubMed ID: 28726812
[TBL] [Abstract][Full Text] [Related]
10. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
Wenger TL; Bly RA; Wu N; Albert CM; Park J; Shieh J; Chenbhanich J; Heike CL; Adam MP; Chang I; Sun A; Miller DE; Beck AE; Gupta D; Boos MD; Zackai EH; Everman D; Ganapathi S; Wilson M; Christodoulou J; Zarate YA; Curry C; Li D; Guimier A; Amiel J; Hakonarson H; Webster R; Bhoj EJ; Perkins JA; Dahl JP; Dobyns WB
Am J Med Genet A; 2020 Jul; 182(7):1576-1591. PubMed ID: 32500973
[TBL] [Abstract][Full Text] [Related]
11. Acro-osteolysis, keloid like-lesions, distinctive facial features, and overgrowth: two newly recognized patients with premature aging syndrome, Penttinen type.
Zufferey F; Hadj-Rabia S; De Sandre-Giovannoli A; Dufier JL; Leheup B; Schweitze C; Bodemer C; Cormier-Daire V; Le Merrer M
Am J Med Genet A; 2013 Jul; 161A(7):1786-91. PubMed ID: 23720404
[TBL] [Abstract][Full Text] [Related]
12. Expansion of the phenotype of Kosaki overgrowth syndrome.
Minatogawa M; Takenouchi T; Tsuyusaki Y; Iwasaki F; Uehara T; Kurosawa K; Kosaki K; Curry CJ
Am J Med Genet A; 2017 Sep; 173(9):2422-2427. PubMed ID: 28639748
[TBL] [Abstract][Full Text] [Related]
13. The
Tran TH; Nguyen JV; Stecula A; Akutagawa J; Moorman AV; Braun BS; Sali A; Mullighan CG; Shah NP; Dai Y; Devidas M; Roberts KG; Smith CC; Loh ML
Haematologica; 2021 Aug; 106(8):2242-2245. PubMed ID: 33626861
[No Abstract] [Full Text] [Related]
14. Kosaki overgrowth syndrome: A newly identified entity caused by pathogenic variants in platelet-derived growth factor receptor-beta.
Takenouchi T; Okuno H; Kosaki K
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):650-657. PubMed ID: 31710779
[TBL] [Abstract][Full Text] [Related]
15. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Schuetze SM; Bolejack V; Thomas DG; von Mehren M; Patel S; Samuels B; Choy E; D'Amato G; Staddon AP; Ganjoo KN; Chow WA; Rushing DA; Forscher CA; Priebat DA; Loeb DM; Chugh R; Okuno S; Reinke DK; Baker LH
JAMA Oncol; 2018 Jun; 4(6):814-820. PubMed ID: 29710216
[TBL] [Abstract][Full Text] [Related]
16. The Master of Puppets: Pleiotropy of PDGFRB and its Relationship to Multiple Diseases.
Moura DAP; de Oliveira JRM
J Mol Neurosci; 2020 Dec; 70(12):2102-2106. PubMed ID: 32613555
[TBL] [Abstract][Full Text] [Related]
17. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia.
Hamada T; Iriyama N; Takahashi H; Miura K; Uchino Y; Nakagawa M; Hatta Y; Takei M
Clin Drug Investig; 2018 Sep; 38(9):813-818. PubMed ID: 29943365
[TBL] [Abstract][Full Text] [Related]
20. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
